Long-term renal function in primary hypertension: An epidemiological and pathophysiological study

Scandinavian Journal of Urology and Nephrology, Supplement

Volumn 33, Issue 199, 1999, Pages 1-36

  Siewert Delle, Annica ^a  

^a NONE

Author keywords

Birth weight; Blood pressure; Body mass index; End stage renal disease; Epidemiology; Gestational age; Glomerular filtration rate; Population based; Primary hypertension; Renal blood flow; Renal vascular resistance; Urinary albumin excretion

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FELODIPINE; HYDROCHLOROTHIAZIDE; METOPROLOL; RAMIPRIL; THIAZIDE DIURETIC AGENT;

ADULT; ANTIHYPERTENSIVE THERAPY; BIRTH WEIGHT; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; GESTATIONAL AGE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; KIDNEY VASCULAR RESISTANCE; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME; URINARY EXCRETION; ARTICLE; CHRONIC KIDNEY FAILURE; FOLLOW UP; KIDNEY; MASS SCREENING; MIDDLE AGED; PREVALENCE; RISK FACTOR; SWEDEN; TIME;

ANTIHYPERTENSIVE AGENTS; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; MASS SCREENING; MIDDLE AGED; PREVALENCE; RISK FACTORS; SWEDEN; TIME FACTORS;

EID: 0032617127     PISSN: 03008886     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (190)

1. 1. Agewall S, Wikstrand J, Ljungman S, Herlitz H, Fagerberg B. On behalf of the Risk Factor Intervention Study Group. Does microalbuminuria predict cardiovascular events in non-diabetic men with treated hypertension? Am J Hypertens 1995; 8: 337-42.
2. 2. Andersson Jr G, Blakeman N, Streeten D. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens 1994; 12: 609-15.
3. 3. Andersson S, Meyer TW, Rennke HG, Brenner BM. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 1985; 76: 612-19.
4. 4. Andersson O, Berglund G, Hansson L, Sannerstedt R, Sivertsson R, Wikstrand J, et al. Organisation and efficacy of an out-patient hypertension clinic. Acta Med Scand 1978; 203: 391-8.
5. 5. Andersson OK, Hedner T, Granerus G. Felodipine in combination with a β-blocker and a diuretic in chronic treatment of patients with refractory primary hypertension. Drugs 1987; 34 (Suppl. 3): 156-60.
6. 6. Aurell M, Bengtsson C, Björck S. Enalapril versus metoprolol in primary hypertension-effects on the glomerular filtration rate. Nephrol Dial Transplant 1997; 2: 2289-94.
7. 7. Barker DJP, Osmond C. Death rates from stroke in England and Wales predicted from past maternal mortality. Br Med J 1987; 295: 83-6.
8. 8. Barker DJP, Osmond C, Golding J, Kuh D. Wadsworth MEJ. Growth in utero, blood pressure in childhood and adult life, and mortality from cardiovascular disease. Br Med J 1989; 298: 564-7.
9. 9. Barker DJP, Bull AR, Osmond C, Simmonds SJ. Fetal and placental size and risk of hypertension in adult life. Br Med J 1990; 301: 259-62.
10. 10. Barker DJP, Osmonds C, Simmonds SJ, Wield GA. The relation of small head circumference and thinness at birth to death from cardiovascular disease in adult life. Br Med J 1993; 306: 422-6.
11. 11. Bauer JH, Brooks CS, Bunch RN. Renal function and haemodynamic studies in low- and normal-renin essential hypertension. Arch Intern Med 1982; 142: 1317-23.
12. 12. Bauer JH, Reams GR. Renal effects of angiotensin converting enzyme inhibitors in hypertension. Am J Med 1986; 81 (Suppl. 4C): 19-27.
13. 13. Bauer JH, Reams GP, Lal SM. Renal protective effect of strict blood pressure control with enalapril therapy. Arch Intern Med 1987; 147: 1397-400.
14. 14. Benediktsson R, Lindsay RS, Noble J, Seckl JR, Edwards CR. Glucocorticoid exposure in utero: new model for adult hypertension. Lancet 1993; 341: 339-41.
15. 15. Bergluad G, Andersson O, Wilhelmsen L. Prevalence of primary and secondary hypertension: studies in a random population sample. Br Med J 1976; 2: 554-6.
16. 16. Bianchi G, Cusi D, Gatti M, Lupi GP, Ferrari P, Barlassina C, et al. A renal abnormality as a possible cause of "essential hypertension". Lancet 1979; 1: 173-5.
17. 17. Bianchi S, Bigazzi R, Baldari G, Campese VM. Microalbuminuria in patients with essential hypertension: effect of an angiotensin converting enzyme inhibitor and of a calcium channel blocker. Am J Hypertens 1991; 4: 291-6.
18. 18. Bianchi S, Bigazzi R, Baldari G, Campese VM. Microalbuminuria in patients with essential hypertension: Effects of several antihypertensive drugs. Am J Med 1992; 93: 525-8.
19. 19. Bigazzi R, Bianchi S, Campese VM, Baldari G. Prevalence of microalbuminuria in a large population of patients with mild to moderate essential hypertension. Nephron 1992; 61: 94-7.
20. 20. Bigazzi R, Bianchi S, Baldari D, Sgherri G, Baldari G, Campese VM. Long-term effects of a converting enzyme inhibitor and a calcium channel blocker on urinary albumin excretion in patients with essential hypertension. Am J Hypertens 1993; 6: 108-13.
21. 21. Birkenhäger WH, Schalekamp MADH Control mechanisms in essential hypertension. New York/Amsterdam: Elsevier Scientific 1976: 43-62.
22. 22. Blair D, Habicht JP, Sims EA, Sylwester D, Abraham S. Evidence for an increased risk for hypertension with centrally located body fat and the effect of race and sex on this risk. Am J Epidemiol 1984; 119: 526-40.
23. 23. Brenner BM, Garcia DL, Anderson S. Glomeruli and blood pressure. Less of one, more the other? Am J Hypertens 1988; 1: 335-47.
24. 24. Brenner BM, Chertow GM. Congenital oligonephropathy and the etiology of adult hypertension and progressive renal injury. Am J Kidney Disease 1994; 23: 171-5.
25. 25. Brenner BM, Mackenzie H. Nephron mass as a risk factor for progression of renal disease. Kidney Int 1997; 52 (Suppl. 63): 124-7.
26. 26. Brunner FP, Selwood NHon behalf of the EDTA Registration Committee. Profile of patients on RRT in Europe and death rates due to major causes of death groups. Kidney Int 1992; 42 (Suppl. 38): 4-15.
27. 27. Bühler FR, Burkart F, Lütold BE, Küng M, Marbet G, Pfisterer M. Antihypertensive β-blocking action as related to renin and age: a pharmacologic tool to identify pathogenetic mechanisms in essential hypertension. Am J Cardiol 1975; 36: 653-69.
28. 28. Brod J, Fencl V, Hejl Z, Jirka J, Ulrych M. General and regional haemodynamic pattern underlying essential hypertension. Clin Sci 1962; 23: 339-49.
29. 29. Carmines PK, Morrison TK, Navar LG. Angiotensin II effects on microvascular diameters of in vitro bloodperfused juxtamedullary nephrons. Am J Physiol 1986; 251: 610-8.
30. 30. Chamontin B, Poggi L, Lang T, Ménard J, Chevalier H, Gallois H, et al. Prevalence, treatment and control of hypertension in the French population. Data from a survey on high blood pressure in general practice, 1994. Am J Hypertens 1998; 11: 759-62.
31. 31. Chasis H, Baldwin DS. The kidney in essential hypertension. Victim or culprit. Circulation 1966; 34: 921-4.
32. 32. Chockalingam A, Fodor GJ. Treatment of raised blood pressure in the population. The Canadian Experience. Am J Hypertens 1998; 11: 747-9.
33. 33. Christy NP, Shaver JC. Estrogens and the kidney. Kidney Int 1974; 6: 366-76.
34. 34. Coca A. Control of acterial hypertension in Spain. Results of the Controlpres 95 Study. Hypertension 1995; 12: 182-8.
35. 35. Collins IR, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, et al. Epidemiology: blood pressure, stroke, and coronary heart disease. II. Short-term reduction in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-38.
36. 36. Criqui MH, Wallace RB, Mishkel M, Barrett-Connor E, Heiss G. Alcohol consumption and blood pressure: the Lipid Research Clinics Prevalence study. Hypertension 1981; 3: 557-65.
37. 37. Curhan GC, Chertow GM, Willett WC, Spiegelman D, Colditz GA, Manson JE, et al. Birth weight and adult hypertension and obesity in women. Circulation 1996; 94: 1310-15.
38. 38. Davies DF, Shock NW. Age changes in glomerular filtration rate, effective renal plasma flow and tubular excretory capacity in adult males. J Clin Invest 1950; 29: 496-507.
39. 39. Dawber TR, Kannel WB, Kagan A, Donabodian RK, McNamara PM, Pearson. Environmental factors in hypertension. In: Stamler J, Stamler R, Pullman TN, editors. The epidemiology of hypertension. New York: Grunne & Stratton, 1967: 255-82.
40. 40. de Leeuw PW, Kho TL, Falke HE, Birkenhäger WH, Wester A. Haemodynamic and endocrinological profile of essential hypertension. Acta Med Scand 1978; (Suppl. 622): 1-61.
41. 41. de Leeuw PW, Birkenhäger WH. Renal response to propranolol treatment in hypertensive humans. Hypertension 1982; 4: 125-31.
42. 42. de Zeeuw D, Navis GJ, Donker AJM, de Jong PE. The angiotensin converting enzyme inhibitor enalapril and its effects on renal function. J Hypertens 1983; 1 (Suppl. 1): 93-7.
43. 43. Dupont AG, Van der Niepen P, Volekaert A, Ingels M, Bossuyt AM, Jonckheer MH, et al. Improved renal function during chronic lisinopril treatment in moderate to severe primary hypertension. J Cardiovasc Pharmacol 1987; 10 (Suppl. 7): 148-50.
44. 44. Edwards CR, Benediktsson R, Liadsay RS, Seckl RJ. Dysfunction of placental ghicocorticoid barrier: link between fetal environment and adult hypertension? Lancet 1993; 341: 355-7.
45. 45. Entwisle G, Apostolides AY, Hebel J, Henderson MM. Target organ damage in black hypertensives. Circulation 1977; 55: 792-6.
46. 46. Erley CM, Haefele VWE, Braun N, Risler T. Microalbuminuria in essential hypertension reduction by different antihypertensive drugs. Hypertens 1993; 21: 810-5.
47. 47. Evans JG, Rose G. Hypertension. Br Meal Bull 1971; 27: 37-42.
48. 48. Fagerberg B, Andersson OK, Isaksson B, Björntorp P. Blood pressure control during weight reduction in obese hypertensive men: separate effects of sodium and energy restriction. Br Med J 1984; 288: 11-4.
49. 49. Falch DK, Ødegaard AE, Norman N. Renal plasma flow and cardiac output during hydralazine and propranolol treatment in essential hypertension. Scand J Clin Lab Invest 1978; 38: 143-6.
50. 50. Folkow B, Hallbäck M, Lundgren Y, Weiss L. Renal vascular resistance in spontaneously hypertensive rats. Acta Physiol Scand 1971; 83: 96-105.
51. 51. Folkow B. Salt and hypertension. News Physiol Sci 1990; 5: 220-4.
52. 52. Gennser G, Rymark P, Isberg PE. Low birth weight and risk of high blood pressure in adulthood. Br Med J 1988; 296: 1498-500.
53. 53. Giaconi S, Levanti C, Fommei E, Innocenti F, Seghieri G, Palla L, et al. Microalbuminuria and casual and ambulatory blood pressure monitoring in normotensives, and in patients with borderline and mild essential hypertension. Am J Hypertens 1989; 2: 259-61.
54. 51Cr-EDTA clearance as a measure of glomerular filtration rate. Scand J Clin Lab Invest 1981; 41: 611-16.
55. 55. Grimm HR, Svendsen KH, Kasiske B, Keane WF, Wahi MM for the MRFIT research group. Proteinuria is a risk factor for mortality over 10 years of follow-up. Kidney Int 1997; 52 (Suppl. 63): 10-4.
56. 56. Guazzi MD, DeCesare N, Galli C, Salvioni A, Tramontana C, Tamborini G, et al. Calcium-channel blockade with nifedipine and angiotensin converting-enzyme inhibition with captopril in the therapy of patients with severe primary hypertension. Circulation 1984; 70: 279-84.
57. 57. Guyton AC, Coleman TG. A quantitative analysis of the pathophysiology of hypertension. Circ Res 1969; 24 (Suppl. 5): 1-19.
58. 58. Guyton AC, Coleman TG, Cowley AW, Scheel KW, Manning Jr RD, Norman Jr RA. Arterial pressure regulation. Overriding dominance of the kidneys in long-term regulation and in hypertension. Am J Med 1972; 52: 584-94.
59. 59. Guyton AC, Hall JE. Urine formation by the kidneys. I. Glomerular filtration, renal blood flow, and their control. Textbook of medical physiology, 9th ed. Philadelphia: WB Saunders, 1996: 393-405.
60. 60. Haffner SM, Stern MP, Gruber MK, Hazdu HP, Mithcell BD, Patterson JK. Microalbuminuria: potential marker for increased cardiovascular risk factors in non-diabetic subjects? Arteriosclerosis 1990; 10: 727-31.
61. 61. Hales CN, Barker DJP, Clark PM, Cox LJ, Fall C, Osmond C. et al. Fetal and infant growth and impaired glucose tolerance at age 64. Br Med J 1991; 303: 1019-22.
62. 62. Hall JE, Brands MW, Dixon WN, Smith MJ, et al. Obesity-induced hypertension. Renal function and systemic haemodynamics. Hypertension 1993; 22: 292-9.
63. 63. Hansson L, Zanchetti A, Carruthers GS, Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensified blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-62.
64. 64. Hartford M, Wikstrand J, Wallentin I, Ljungman S, Wilhelmsen L, Berglund G. Non-invasive signs of cardiac involvement in essential hypertension. Eur Heart J 1982; 3: 75-87.
65. 65. Hartford M, Wendelhag I, Berglund G, Wallentin I, Ljungman S, Wikstrand J. Cardiovascular and renal effects of long-term antihypertensive treatment. JAMA 1988; 259: 2553-7.
66. 66. Havlik RJ, Feinleib M. Epidemiology and genetics of hypertension. Hypertension 1982; 4 (Suppl. III): 121-7.
67. 67. Herlitz H, Björck S, Nyberg G, Granerus G, Aurell M. Clinical evaluation of felodipine in patients with refractory hypertension. Drugs 1987; 34 (Suppl. 3): 151-5.
68. 68. Hinchliffe SA, Lynch MR, Sargent PH, Howard CV, Vanvelzen D. The effects of intrauterine growth retardation on the development of renal nephrons. Br J Obstet Gynaecol 1992; 99: 296-301.
69. 69. Hollenberg NK, Adams DF, Solomon H, Chenitz WR, Burger BM, Abrams HL, et al. Renal vascular tone in essential and secondary hypertension. Medicine 1975; 54: 29-44.
70. 70. Hollenberg NK, Swartz SL, Passan DR, Williams GH. Increased glomerular filtration rate after converting-enzyme inhibition in essential hypertension. N Engl J Med 1979; 301: 9-12.
71. 71. Hollenberg NK, Williams GH, Adams DF. Essential hypertension: abnormal renal vascular and endocrine response to a mild psychological stimulus. Hypertension 1981; 3: 11-7.
72. 72. Hollenberg NK. Renal haemodynamics in essential and renovascular hypertension. Influence of captopril. Am J Med 1984; 76: 22-8.
73. 73. Holley KE, Hunt JC, Brown AL, Kincaid OW, Sheps SG. Renal artery stenosis: a clinical-pathologic study in normotensive and hypertensive patients. Am J Med 1996; 37: 14-22.
74. 74. Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol 1981; 241: 85-93.
75. 75. Hulthén L, Katzrnan P. Renal effects of acute and long-term treatment with felodipine in essential hypertension. J Hypertens 1988; 6: 231-7.
76. 76. HDFP. Hypertension Detection and Follow-up Program Cooperative Group: a progress report. Circ Res 1977; 40 (Suppl. 1): 106-9.
77. 77. Ibsen H, Sederberg-Olsen P. Changes in glomerular filtration rate during long-term treatment with propranolol in patients with arterial hypertension. Clin Sci 1973; 44: 129-34.
78. 78. Isaksson B. A simple formula for the mental arithmetic of the human body surface area. Scand J Clin Lab Invest 1958; 10: 283-9.
79. 79. JNC VI. Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Sixth Report on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-45.
80. 80. Kannel WB, Stampfer MJ, Castelli WP, Verter J. The prognostic significance of proteinuria: the Framingham study. Am Heart J 1994; 108: 1347-52.
81. 81. Kashgarian M. Hypertensive disease and kidney structure. In: Laragh JH, Brenner BM, editors. Hypertension pathophysiology, diagnosis and management. 2nd ed. New York: Raven Press, 1995: 433-43.
82. 82. Katzman PL, Henningsen NC, Fagher B, Thulin T, Hulthén UL. Renal and endocrine effects of long-term converting enzyme inhibition as compared with calcium antagonism in essential hypertension. J Cardiovasc Pharmacol 1990; 15: 360-4.
83. 83. Kimura G, Deguchi F, Kojima S, Ashida T, Yoshimi H, Hitoshi A, et al. Effect of a calcium-entry blocker, nicardipine, on intrarenal haemodynamics in essential hypertension. Am J Kidney Dis 1991; 17: 47-54.
84. 84. Kiowski W, Bertel O, Erne P, Bolli P, Hultén UL, Ritz R, et al. Hemodynamic and reflex responses to acute and chronic antihypertensive therapy with the calcium entry blocker nifedipine. Hypertension 1983; 5 (Suppl. I): 70-4.
85. 85. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 331: 13-8.
86. 86. Langman J Medical embryology. 3rd ed. Baltimore: Williams & Wilkins, 1975: 81.
87. 87. Laragh JH, Pickering TG. Essential hypertension. In: Brenner BM, Rector FC, editors. The kidney. 4th ed. Philadelphia: WB Sounders, 1991: 1909-39.
88. 88. Laurell CB. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 1966; 15: 45-52.
89. 89. Law CM, de Swiet M, Osmond C, Fayers PM, Barker DJP, Cruddas AM, et al. Initiation of hypertension in utero and its amplification throughout life. Br Med J 1993; 306: 24-7.
90. 90. Lederballe Pedersen O, Mikkelsen E, Christensen NJ, Kornerup HJ, Pedersen EB. Effect of nifedipine on plasma renin, aldosterone and catecholamines in arterial hypertension. Eur J Clin Pharmacol 1979; 15: 235-40.
91. 91. Leon DA, Koupilova I, Lithell HO, Berglund L, Mohsen R, Vågerö D, et al. Failure to realise growth potential in utero and adult obesity in relation to blood pressure in 50-year-old Swedish men. Br Med J 1996; 312: 401-6.
92. 92. Leon DA, Lithell HO, Vågerö D, Koupilová I, Moshen R, Berglund L, et al. Reduced fetal growth rate and increased risk of death from ischaemic heat disease: cohort study of 15 000 Swedish men and women born 1915-29. Br Med J 1998; 317: 241-5.
93. 93. Leonetti G, Mayer G, Morganti A, Terzoli L, Zanchetti A, Bianchetti G, et al. Hypotensive and renin-suppressing activities of propranolol in hypertensive patients. Clin Sci Mol Med 1975; 48: 491-9.
94. 94. Levy SB, Talner LB, Cool MN, Holle R, Stone RA. Renal vasculature in essential hypertension: racial differences. Ann Intern Med 1978; 88: 12-6.
95. 95. Lindeman RD, Tobin JD, Shock NW. Association between blood pressure and the rate of decline in renal function with age. Kidney Int 1984; 26: 861-8.
96. 96. Ljungman S, Aurell M, Hartford M, Wikstrand J, Wilhelmsen L, Berglund G. Blood pressure and renal function. Acta Med Scand 1980; 208: 17-25.
97. 97. Ljungman S, Aurell M, Hartford M, Wikstrand J, Wilhelmsem L, Berglund G. Sodium excretion and blood pressure. Hypertension 1981; 3: 318-26.
98. 98. Ljungman S. Renal function, sodium excretion and the renin-angiotensin-aldosterone system in relation to blood pressure. An epidemiological and physiological study. Acta Med Scan 1982; (Suppl. 663): 1-68.
99. 99. Ljungman S, Aurell M, Hartford M, Wikstrand J, Berglund G. Effects of subpressor doses of angiotensin II on renal haemodynamics in relation to blood pressure. Hypertension 1983; 5: 368-74.
100. 100. Ljungman S. Microalbuminuria in essential hypertension. Am J Hypertens 1990; 3: 956-60.
101. 101. Ljungrnan S, Wikstrand J, Hartford M, Aurell M, Lindstedt G, Berglund G. Effects of long-term antihypertensive treatment and aging on renal function and albumin excretion In primary hypertension. Am J Hypertens 1993; 6: 554-63.
102. 102. Ljungman S, Wikstrand J, Hartford M, Berglund G. Urinary albumin excretion - A predictor of risk of cardiovascular disease. Am J Hypertens 1996; 9: 770-8.
103. 103. London GM, Safar ME, Sassard JE, Levenson JA, Simon AC. Renal and systemic haemodynamics in sustained essential hypertension. Hypertens 1984; 6: 743-54.
104. 104. Lopes AA, Port FK. The low birth weight hypothesis as a plausible explanation for the black/white differences in hypertension, non-insulin-dependent diabetes, and end-stage renal disease. Am J Kidney Dis 1995; 25: 350-6.
105. 105. Macdonald MS, Emery JL. The late intrauterine and postnatal development of human renal glomeruli. J Anat 1959; 93: 331-40.
106. 106. Macintyre S, Watt G, West P, Ecob R. Correlates of blood pressure in 15-year-olds in the West of Scotland. J Epidemiol Commun Health 1991; 45: 143-7.
107. 107. Mackenzie HS, Lawler EV, Brenner BM. Congenital oligonephropathy: the fetal flaw in essential hypertension? Kidney Int 1996; 49 (Suppl. 55): 30-4.
108. 108. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke and coronary heart disease. I. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-74.
109. 109. Martyn CN, Barker DJP, Jespersen S, Greenwald S, Osmond C, Berry C. Growth in utero, adult blood pressure, and arterial compliance. Br Heart J 1995; 73: 116-21.
110. 110. Matthes JW, Lewis PA, Davies DP, Bethel JA. Relation between birth weight at term and systolic blood pressure in adolescence. Br Med J 1994; 308: 1074-7.
111. 111. McClellan W, Tuttle E, Issa A. Racial differences in the incidence of hypertensive end-stage renal disease (ESRD) are not entirely explained by differences in the prevalence of hypertension. Am J Kidney Dis 1988; 12: 285-90.
112. 112. McKenna MJ, Arias C, Feldkamp CS, Whitehouse FW. Microalbuminuria in clinical practice. Arch Intern Med 1991; 151: 1745-7.
113. 113. Miall WE, Chinn S. Blood pressure and ageing: results of a 15-17 year follow-up study in South Wales. Clin Sci Mol Med 1973; 45 (Suppl. 1): 23-33.
114. 114. Mitch WE, Walser M, Buffington GA, Leman Jr J. A simple method of estimating progression of chronic renal failure. Lancet 1976; 2: 1326-8.
115. 115. Mitchell HC, Graham RM, Pettinger WA. Renal function during long-term treatment of hypertension with minoxidil. Comparison of benign and malignant hypertension. Ann Intern Med 1980; 93: 676-7.
116. 116. Moiseyev VS, Ivleva AJ, Antija ID, Gavrilova EN. Cardiovascular and renal effects of ramipril. Lancet 1989; i: 846.
117. 117. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early morbidity in maturity-onset diabetes. N Engl J Med 1984; 310: 356-60.
118. 118. Morton JJ, Webb DJ. Measurement of plasma angiotensin II. Clin Sci 1985; 68: 483-4.
119. 119. Nigam SK, Aperia AC, Brenner BR. Development and maturation of the kidney. In: Brenner BM, Rector FC, editors. The kidney. Philadelphia: WB Saunders, 1996: 72-98.
120. 120. NHANES III. National Center for Health Statistics: plan and operation of the third National Health and Nutrition Examination survey, 1988-94. US Dept of Health and Human Services Publication (PHS). Vital Health Stat 1994; 1(32): 94-1308.
121. 121. Olsson G, Tuornilehto J, Berglund G, Elmfeldt D, Warnold I, Barber H, et al. Primary prevention of sudden cardiovascular death in hypertensive patients. Mortality results from the MAPHY study. Am J Hypertens 1991; 4: 151-8.
122. 122. Opsahl JA, Abraham PA, Halstenson CE, Keane WF. Correlation of office and ambulatory blood pressure measurements and urinary albumin and N-acetyl-β-D-glucosaminidase excretions in essential hypertension. Am J Hypertens 1988; 1: 117-20.
123. 123. Parving HH, Gyntelberg F. Transcapillary escape rate of albumin and plasma volume in essential hypertension. Circ Res 1973; 32: 643-51.
124. 124. Parving HH, Jensen HAE, Mogensen CE, Evrin PE. Increased urinary albumin excretion rate in benign essential hypertension. Lancet 1974; i: 1196-92.
125. 125. Pattersson RP, Whelton PK. Hypertension in chronic renal failure. Am J Nephrol 1983; 3: 185-92.
126. 126. Pedersen EB. Glomerular filtration rote and renal plasma flow in patients with essential hypertension before and after treatment with alprenolol. Acta Med Scand 1975; 198: 365-71.
127. 127. Pedersen EB, Mogensen CE. Effect of antihypertensive treatment on urinary albumin excretion, glomerular filtration rate, and renal plasma flow in patients with essential hypertension. Scand J Clin Lab Invest 1976; 36: 231-7.
128. 128. Pedersen EB. Abnormal renal haemodynamics during exercise in young patients with mild essential hypertension without treatment and during long-term propranolol therapy. Scand J Clin Lab Invest 1978; 64: 567-71.
129. 129. Perera GA. Hypertensive vascular disease; description and natural history. J Chron Dis 1955; 1: 33-42.
130. 130. Perneger TV, Klag MJ, Feldman HI, Whelton PK. Project of hypertension-related renal disease in middle-aged residents of the United States. JAMA 1993; 269: 1272-7.
131. 131. Pettinger WA, Lee HC, Reisch J, Mitchell HC. Long-term improvement in renal function after short term strict blood pressure control in hypertensive nephrosclerosis. Hypertension 1989; 13: 766-72.
132. 132. Reams GP, Hamory A, Lau A, Bauer JH. Effect of nifedipine on renal function in patients with essential hypertension. Hypertension 1988; 11: 452-6.
133. 133. Reubi FC, WeJdmann P, Hodler J, Cottier P. Changes in renal function in essential hypertension. Am J Med 1978; 64: 556-63.
134. 134. Romero JC, Raij L, Granger JP, Ruilope LM, Rodicio JL. Multiple effects of calcium entry blockers on renal function in hypertension. Hypertension 1987; 10: 140-51.
135. 135. Rose GA, Blackburn H. Cardiovascular survey methods. WHO Monogr 1968; Ser 56.
136. 136. Rostand SG, Kirk KA, Rutsky EA, Pate BA. Racial differences in the incidence of treatment for end-stage renal disease. N Engl J Med 1982; 306: 1276-9.
137. 137. Rostand SG, Brown G, Kirk KA, Rutsky EA, Dustan HP. Renal insufficiency in treated essential hypertension. N Engl J Med 1989; 320: 684-8.
138. 138. Ruilope LM, Alcazar JM, Rodicio JL. Consequences of arterial hypertension. J Hypertens 1992; 10 (Suppl. 7): 85-90.
139. 139. Ruilope LM, Alcázar JM, Hernández E, Praga M, Lahera V, Rodicio JL. Long-term influences of antihypertensive therapy on microalbuminuria in essential hypertension. Kidney Int 1994; 45 (Suppl. 45): 171-3.
140. 140. SBU. Moderately elevated blood pressure. A report from the Swedish Council on Technology Assessment in Health Care. J Int Med 1995; 238 (Suppl. 737): 1-225.
141. 141. Safar ME, Chau PN, Weiss AY, London GM, Milliez PL. Control of cardiac output in essential hypertension. Am J Cardiol 1976; 38: 332-6.
142. 142. Samulsson O, Wikstrand J, Wilhelmsen L, Berglund G. Heart and kidney involvement daring antihypertensive treatment. Acta Med Scand 1984; 215: 305-11.
143. 143. Samuelsson O. Hypertension in middle-aged men. Management, morbidity and prognostic factors during long-term hypertensive care. Acta Med Scand 1985a; (Suppl. 702): 1-79.
144. 144. Samuelsson O, Wilhelmsen L, Elmfeldt D, Pennert K, Wedel H, Wikstrand J, et al. Predictors of cardiovascular morbidity in treated hypertension: results from the Primary Preventive Trial in Göteborg, Sweden. J Hypertens 1985b; 3: 167-76.
145. 145. Samuelsson O. Prevalence of hypertension in Sweden. J Int Med 1995; 238 (Suppl. 737): 129-33.
146. 146. Sannerstedt R, Conway J. Haemodynamic and vascular response to antihypertensive treatment with adrenergic blocking agents: a review. Am Heart J 1970; 79: 122-7.
147. 147. Schulman NB, Ford CE, Hall DW, Blaufox M, Simon D, Langford HG, et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the Hypertension Detection and Follow-up Program. Hypertension 1989; 13 (Suppl. I): 80-93.
148. 148. Seidman DS, Laor A, Gale R, Stevenson DK, Mashiach S, Danon YL. Birth weight, current body weight, and blood pressure in late adolescence. Br Med J 1991; 302: 1235-7.
149. 149. Shimamatsu K, Onoyama K, Harade A, Kumagai H, Hirakata H, Miishima C, et al. Effects of blood pressure on the progression rate of renal impairment in chronic glomerulonephritis. J clin Hypertens 1985; 1 (Suppl.): 239-44.
150. 150. Smith HW. The kidney. Structure and function in health and disease. New York: Oxford University Press, 1951: 814-35.
151. 151. Sommers SC, Melamed J. Renal pathology of essential hypertension. Am J Hypertens 1990; 3: 583-7.
152. 152. Sowers JR, Whiffield LA, Catania RA, Stern N, Tuck ML, Dornfield L, et al. Role of the sympathetic nervous system in blood pressure maintenance in obesity. J Clin Endocrinol Metab 1982; 54: 1181-6.
153. 153. SRAU. The Swedish register for dialysis and kidney transplantation. 1998. Schön S, Dept. of Nephrology, KSS, S-541 Skövde, Sweden.
154. 154. Stamler J, Berkson DM, Lindberg HA. Socioeconomic factors in the epidemiology of hypertension disease. In: Stamler J. Stamler R, Pullman TN, editors. The epidemiology of hypertension. New York: Grunne & Stratton, 1967: 289-313.
155. 155. Stamler J, Neaton JD, Wentworth DN. Blood pressure (systolic and diastolic) and risk of fatal coronary heart disease. Hypertension 1989; 13 (Suppl. I): 2-12.
156. 156. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic and cardiovascular risks. US population data. Arch Intern Med 1993; 153: 598-615.
157. 157. Strandgaard S, Elmgreen J, Christensen TE, Laursen SW. Effect of short-term and long-term treatment with metoprolol on renal blood flow and glomerular filtration rate in hypertensive patients with a normal kidney function. Danish Medical Bulletin. Journal of the Health Sciences (Copenhagen) 1982; 29: 287-9.
158. 158. Sunderrajan S, Reams G, Bauer JH. Long-term renal effects of diltiazem in essential hypertension. Am Heart J 1987; 114: 383-8.
159. 159. Sugino G, Barg AP, O'Connor DT. Renal perfusion is preserved during cardioselective β-blockade with metoprolol in hypertension. Am J Kidney Dis 1984; 3: 357-61.
160. 160. Svärdsudd K, Tibblin G. A longitudinal blood pressure study. Change of blood pressure during ten years in relation to initial value. The study of men born in 1913. Thesis, University of Gothenburg, Sweden, 1978.
161. 161. Tanaka H, Hayaashi M, Date C, Imai K, Asada M, Hironobu S, et al. Epidemiologic studies of stroke in Shibata, a Japanese provincial city: preliminary report on risk factors for cerebral infarction, Stroke 1985; 16: 773-80.
162. 162. Tibblin G. High blood pressure in men aged 50 - A population study of men born in 1913. Acta Med Scand 1967; (Suppl. 470): 69-70.
163. 163. Tobian L. Does essential hypertension lead to renal failure? Am J Catdiol 1987; 60: (Suppl. I): 42-6.
164. 164. Tracy RE, Mercante DE, Moadada A, Berenson G. Quantification of hypertension nephrosclerosis on an objective rational scale of measure in adults and children. Am J Clin Pathol 1986; 85: 312-8.
165. 165. Tracy RE, Bhandura SY, Oalmann MC, Guzman MA, Newman WP. Blood pressure and nephrosclerosis in black and white men and women aged 25-54. Modern Pathol 1991; 4: 602-9.
166. 166. Tracy RE, Berenson GS, Cuoto-Garcia L, Wattigney WA, Barrett TJ. Nephrosclerosis and aortic arteriosclerosis from age 6 to 70 in the United States and in Mexico. Virchows Arch A 1992; 420: 479-88.
167. 167. U.S. Renal Data System, in USRDS 1997 Annual Data Report. The national institutes of Health, The National Institute of Diabetes and Digestive and Kidney Diseases, Division of Kidney, Urologic, and Hematologic Disease, 1997.
168. 168. Vendemia F, Fornasieri A, Velis O. Different prevalence rates of hypertension in various reno-parenchymal diseases. In: Blaufox MD, Bianchi C, editors. Secondary forms of hypertension. Current diagnosis and management. New York: Grune & Stratton, 1981: 89-94.
169. 169. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressures averaging 115 through 129 mmHg. JAMA 1967; 202: 1028-34.
170. 170. Wadsworth ME, Cripps HA, Midwinter RE, Colley JRT. Blood pressure in a national birth cohort at the age of 36 related to social and familial factors, smoking and body mass. Br Med J 1985; 291: 1534-8.
171. 171. Waschetko NP. Zur frage von dem physiologischen wachstum der niere. Zbl allg Path Anat 1914; 25: 627-28.
172. 172. Weisstuch JM, Dworkin LD. Does essential hypertension cause end-stage renal disease? Kidney Int 1992; 41 (Suppl. 36): 33-7.
173. 173. Wesson LG Physiology of the human kidney. New York: Grunne & Stratton, 1969: 96.
174. 174. Widgren BR, Herlitz H. Aurell M, Berglund G, Wikstrand J, Andersson O. Increased systemic and renal vascular sensitivity to Angiotensin II in normotensive men with positive family history of hypertension. Am J Hypertens 1992; 5: 167-74.
175. 175. Wikstrand J, Berglund G, Wilhelmson L, Wallentin I. Orthogonal electrocardiogram, apex cardiogram and atrial sound in normotensive and hypertensive 50-year-old men. Br Heart J 1976; 38: 779-89.
176. 176. Wikstrand J. Kendall M. The role of β-receptor blockade in preventing sudden death. Eur Heart J 1992; 13 (Suppl. D): 111-20.
177. 177. Wilhelmsen L, Tibblin G, Werkö L. A Primary Preventive Study in Gothenburg, Sweden. Prey Med 1972; 1: 153-60.
178. 178. Wilhelmsen L, Berglund G, Werkö L. Prevalence and management of hypertension in a general population sample of Swedish men. Prev Med 1973; 2: 57-66.
179. 179. Wilhelmsen L, Ljungberg S, Wedel H, Werkö L. A comparison between participants and non-perticipants in a Primary Preventive Trial. J Chron Dis 1976; 29: 331-9.
180. 180. Wilhelmsen L, Berglund G, Elmfeldt D, Tibblin G, Wedel H, Pennert A, et al. The multifactor Primary Prevention Trial in Göteborg, Sweden. Eur Heart J 1986; 7: 279-88.
181. 181. Williams GH, Braunwald E. Hypertensive vascular disease. In: Petersdorf RG, Adams RD, Braunwald E, et al. editors. Harrison's Principles of Internal Medicine. Auckland: McGraw-Hill, 1983: 1487.
182. 182. Whelton PK, He J, Klag MJ. Blood pressure in westernised populations. In: Swales JD, editor. Textbook of hypertension. Oxford: Blackwell Scientific, 1994: 741-747.
183. 183. Whelton PK. Epidemiology of hypertension. Lancet 1994; 344: 101-6.
184. 184. Whincup P, Cook D, Papacosta O, Walker M. Birth weight and blood pressure: cross sectional and longitudinal relations in childhood. Br Med J 1995; 311: 773-6.
185. 185. WHO/ISH Fifth Mild Hypertension Conference. 1993 Guidelines for the management of mild hypertension: memorandum from a World Health Organization/International Society of Hypertension Meeting. J Hypertens 1993; 11: 905-18.
186. 186. WHO. Hypertension control: report of a WHO expert committee. Technical report series, 862. Geneva: World Health Organisation, 1996.
187. 187. Woods JE. Renal function in essential hypertension. Semin Nephrol 1983; 3: 30-9.
188. 188. Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as predictor of vascular disease in non-diabetic subjects: Islington Diabetes Survey. Lancet 1988; 2: 530-3.
189. 189. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. β-blockade during and after myocardial infarction: an overview of the randomized trials. Progr Cardiovasc Dis 1985; 27: 335-71.
190. 190. Zucchelli P, Zuccalà A. Can we accurately diagnose nephrosclerosis? Nephrol Dial Transplant 1995; 10 (Suppl. 6): 2-5.